Evidence map›Paper›PMID 34642780›Full record

ArticleAnalytical and bioanalytical chemistry2022

Current and emerging mass spectrometry methods for the preclinical development of metal-based drugs: a critical appraisal.

Maciej Jarosz, Bernhard K Keppler, Andrei R Timerbaev

Abstract read
PubMed Publisher
In one paragraph

Article in Analytical and bioanalytical chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Maciej JaroszChair of Analytical Chemistry, Warsaw University of Technology, 00664, Warsaw, Poland.
Bernhard K KepplerInstitute of Inorganic Chemistry, University of Vienna, 1090, Vienna, Austria.
Andrei R TimerbaevVernadsky Institute of Geochemistry and Analytical Chemistry, Russian Academy of Sciences, Moscow, 119991, Russian Federation. andrei.timerbaev@univie.ac.at.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This Trends article highlights the multiple ways in which the state-of-the-art molecular mass spectrometry can support the preclinical development of novel metal-based anticancer drugs. Examples from the recent literature-beyond routine characterization applications-are presented to illustrate what analytical and experimental design challenges are to be addressed to facilitate the translation of promising drug candidates to clinical practice.

Indexed as

Antineoplastic AgentsDrug Evaluation, PreclinicalHumansMass SpectrometryMetalsAntineoplastic AgentsMetalsCancer chemotherapyMass spectrometryMetal-based drugs

Identifiers

PMID34642780

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.